Back

The three YTHDF paralogs and VIRMA are the major tumor drivers among the m6A core genes in a pan-cancer analysis

Destefanis, E.; Sighel, D.; Dalfovo, D.; Gilmozzi, R.; Broso, F.; Cappannini, A.; Bujnicki, J. M.; Romanel, A.; Dassi, E.; Quattrone, A.

2024-06-13 cancer biology
10.1101/2024.06.13.598899 bioRxiv
Show abstract

N6-methyladenosine (m6A) is the most abundant internal modification in mRNAs. Despite accumulating evidence for the profound impact of m6A on cancer biology, there are conflicting reports that alterations in genes encoding the m6A machinery proteins can either promote or suppress cancer, even in the same tumor type. Using data from The Cancer Genome Atlas, we performed a pan-cancer investigation of 15 m6A core factors in nearly 10,000 samples from 31 tumor types to reveal underlying cross-tumor patterns. Altered expression, largely driven by copy number variations at the chromosome arm level, results in the most common mode of dysregulation of these factors. YTHDF1, YTHDF2, YTHDF3, and VIRMA are the most frequently altered factors and the only ones to be uniquely altered when tumors are grouped according to the expression pattern of the m6A factors. These genes are also the only ones with coherent, pan-cancer predictive power for progression-free survival. On the contrary, METTL3, the most intensively studied m6A factor as a cancer target, shows much lower levels of alteration and no predictive power for patient survival. Therefore, we propose the non-enzymatic YTHDF and VIRMA genes as preferred subjects to dissect the role of m6A in cancer and as priority cancer targets. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=99 SRC="FIGDIR/small/598899v1_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@1e39eeborg.highwire.dtl.DTLVardef@d6628dorg.highwire.dtl.DTLVardef@e048a6org.highwire.dtl.DTLVardef@c19812_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
NAR Cancer
37 papers in training set
Top 0.1%
26.5%
2
Genome Medicine
183 papers in training set
Top 0.6%
5.5%
3
Cancer Research
130 papers in training set
Top 0.7%
4.8%
4
Nature Communications
5641 papers in training set
Top 32%
4.0%
5
Oncogene
85 papers in training set
Top 0.5%
4.0%
6
npj Precision Oncology
53 papers in training set
Top 0.4%
3.2%
7
Science Advances
1243 papers in training set
Top 10%
3.2%
50% of probability mass above
8
eLife
5828 papers in training set
Top 34%
3.2%
9
Molecular Oncology
55 papers in training set
Top 0.4%
2.6%
10
International Journal of Cancer
49 papers in training set
Top 0.5%
2.1%
11
Nucleic Acids Research
1281 papers in training set
Top 8%
1.9%
12
Cancers
213 papers in training set
Top 3%
1.7%
13
Frontiers in Oncology
103 papers in training set
Top 2%
1.7%
14
Clinical Cancer Research
64 papers in training set
Top 1%
1.5%
15
Cell Reports
1498 papers in training set
Top 22%
1.3%
16
Cancer Discovery
66 papers in training set
Top 1%
1.1%
17
NAR Genomics and Bioinformatics
242 papers in training set
Top 3%
1.1%
18
Cell Death & Disease
126 papers in training set
Top 2%
1.1%
19
Communications Biology
993 papers in training set
Top 22%
1.1%
20
Cell Reports Medicine
153 papers in training set
Top 3%
1.1%
21
Molecular Cancer Research
49 papers in training set
Top 1.0%
1.1%
22
Breast Cancer Research
36 papers in training set
Top 0.5%
1.0%
23
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.6%
0.9%
24
Scientific Reports
3612 papers in training set
Top 74%
0.8%
25
BMC Biology
265 papers in training set
Top 5%
0.8%
26
British Journal of Cancer
49 papers in training set
Top 2%
0.8%
27
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 2%
0.8%
28
Journal of Biological Chemistry
690 papers in training set
Top 9%
0.8%
29
The EMBO Journal
309 papers in training set
Top 8%
0.6%
30
Gut
40 papers in training set
Top 1%
0.6%